CO5680418A2 - Modificaciones estables de maleato acido de tegaserod - Google Patents

Modificaciones estables de maleato acido de tegaserod

Info

Publication number
CO5680418A2
CO5680418A2 CO06016978A CO06016978A CO5680418A2 CO 5680418 A2 CO5680418 A2 CO 5680418A2 CO 06016978 A CO06016978 A CO 06016978A CO 06016978 A CO06016978 A CO 06016978A CO 5680418 A2 CO5680418 A2 CO 5680418A2
Authority
CO
Colombia
Prior art keywords
tegaserod
acid maleate
stable modifications
maleate
stable
Prior art date
Application number
CO06016978A
Other languages
English (en)
Inventor
Sabine Pfeffer
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5680418(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5680418A2 publication Critical patent/CO5680418A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una modificación cristalina A del maleato ácido de tegaserod.2.- Una modificación cristalina A del maleato ácido de tegaserod, caracterizada porque comprende la siguiente estructura cristalina característica, determinada por medio de análisis en un solo cristal, con rayos X: Sistema cristalino triclínico Grupo espacial P-1 a,Å 8.640 b,Å 15.800 c,Å 17.472 aÅ 68.67 ßÅ 88.10 ?Å 88.02 V,Å3 3 2232 Z 4 D(calc.), g/cm3 1.242.
CO06016978A 2003-07-24 2006-02-21 Modificaciones estables de maleato acido de tegaserod CO5680418A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
CO5680418A2 true CO5680418A2 (es) 2006-09-29

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06016978A CO5680418A2 (es) 2003-07-24 2006-02-21 Modificaciones estables de maleato acido de tegaserod

Country Status (24)

Country Link
US (1) US20070112056A1 (es)
EP (2) EP1651601A1 (es)
JP (1) JP2006528609A (es)
KR (1) KR20060040710A (es)
CN (1) CN1826318A (es)
AR (1) AR045081A1 (es)
AU (1) AU2004263285A1 (es)
BR (1) BRPI0412830A (es)
CA (1) CA2532351A1 (es)
CO (1) CO5680418A2 (es)
EC (1) ECSP066306A (es)
IL (1) IL172914A0 (es)
IS (1) IS8321A (es)
MA (1) MA27935A1 (es)
MX (1) MXPA06000917A (es)
MY (1) MY137386A (es)
NO (1) NO20060915L (es)
NZ (1) NZ544596A (es)
PE (1) PE20050253A1 (es)
RU (1) RU2349585C2 (es)
SG (1) SG144944A1 (es)
TN (1) TNSN06024A1 (es)
TW (1) TW200510302A (es)
WO (1) WO2005014544A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582090A1 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
CA2593854A1 (en) * 2005-01-31 2006-08-10 Novartis Ag Organic compounds
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
BRPI0605901A (pt) * 2005-06-22 2007-12-18 Teva Pharma formas polimórficas de maleato de tegaserode
AR058078A1 (es) * 2005-10-06 2008-01-23 Medichem Sa Maleato de tegaserod y procesos de obtencion
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (en) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod maleate free of iodide
EP1956002A1 (en) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. New tegaserod maleate polymorphs and process for their preparation
EP2146958A1 (en) * 2007-05-17 2010-01-27 Generics Ýuk¨Limited Process for the preparation of form a of tegaserod

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
DK1104289T3 (da) * 1998-08-21 2006-05-15 Novartis Ag Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
BRPI0605901A (pt) * 2005-06-22 2007-12-18 Teva Pharma formas polimórficas de maleato de tegaserode

Also Published As

Publication number Publication date
TW200510302A (en) 2005-03-16
ECSP066306A (es) 2006-07-28
NO20060915L (no) 2006-04-24
PE20050253A1 (es) 2005-06-03
MY137386A (en) 2009-01-30
AU2004263285A1 (en) 2005-02-17
AR045081A1 (es) 2005-10-12
SG144944A1 (en) 2008-08-28
US20070112056A1 (en) 2007-05-17
IL172914A0 (en) 2006-06-11
NZ544596A (en) 2009-01-31
KR20060040710A (ko) 2006-05-10
EP1651601A1 (en) 2006-05-03
MXPA06000917A (es) 2006-03-30
RU2006105481A (ru) 2007-09-20
CA2532351A1 (en) 2005-02-17
WO2005014544A1 (en) 2005-02-17
CN1826318A (zh) 2006-08-30
IS8321A (is) 2006-02-22
JP2006528609A (ja) 2006-12-21
BRPI0412830A (pt) 2006-09-26
TNSN06024A1 (en) 2007-10-03
RU2349585C2 (ru) 2009-03-20
EP1880992A1 (en) 2008-01-23
MA27935A1 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
CO5680418A2 (es) Modificaciones estables de maleato acido de tegaserod
CY1109760T1 (el) Παραγωγα ινδολης-3-θειου
TW200407305A (en) Novel compounds
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
NZ235155A (en) Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
PT1379520E (pt) Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
AU5860790A (en) Substituted quinazolinones as angiotensin ii antagonists
CY1108808T1 (el) Ενωσεις μοτιλιδης
MX2007003198A (es) Bolsa soluble en agua que contiene liquido.
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
ATE354622T1 (de) Flüssigkristallines medium
ATE462711T1 (de) Kristalline komplexe von fluticasone 2-furoat
TNSN04138A1 (fr) Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique
TR200100422T2 (tr) Primetanil ihtiva etmekte olan süspansiyon konsantre formülasyon
DE69718469T2 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
EA200401289A1 (ru) Новые противоинфекционные соединения, способы их получения и фармацевтические композиции, содержащие эти соединения
DK0871612T3 (da) Kondenserede isoindoloner som proteinkinase C-inhibitorer
NO20044608L (no) Fremgangsmate for a fremstille konjugert linolsyre
PL352104A1 (en) Oral composition containing perlite
GEP20063936B (en) New anhydrous crystalline forms of gabapentin
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение

Legal Events

Date Code Title Description
FC Application refused